Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fengliao Changweikang Keli versus montmorillonite powder for acute diarrhoea in adults
ChiCTR2400082597Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Apr 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fengliao changweikang in acute diarrhea (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Diarrhoea response rate at 5 days after treatment. Started Apr 2024; status: recruiting.
02
Drugs
fengliao changweikang
03
Conditions
acute diarrhea
Beyond the preview
Go deeper on ChiCTR2400082597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082597.